1. Home
  2. SPRO vs FRGE Comparison

SPRO vs FRGE Comparison

Compare SPRO & FRGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SPRO
  • FRGE
  • Stock Information
  • Founded
  • SPRO 2013
  • FRGE 2014
  • Country
  • SPRO United States
  • FRGE United States
  • Employees
  • SPRO N/A
  • FRGE N/A
  • Industry
  • SPRO Biotechnology: Pharmaceutical Preparations
  • FRGE Computer Software: Prepackaged Software
  • Sector
  • SPRO Health Care
  • FRGE Technology
  • Exchange
  • SPRO Nasdaq
  • FRGE Nasdaq
  • Market Cap
  • SPRO 162.1M
  • FRGE 242.6M
  • IPO Year
  • SPRO 2017
  • FRGE N/A
  • Fundamental
  • Price
  • SPRO $2.20
  • FRGE $16.64
  • Analyst Decision
  • SPRO Buy
  • FRGE Buy
  • Analyst Count
  • SPRO 4
  • FRGE 5
  • Target Price
  • SPRO $5.00
  • FRGE $38.25
  • AVG Volume (30 Days)
  • SPRO 789.2K
  • FRGE 73.6K
  • Earning Date
  • SPRO 08-04-2025
  • FRGE 07-30-2025
  • Dividend Yield
  • SPRO N/A
  • FRGE N/A
  • EPS Growth
  • SPRO N/A
  • FRGE N/A
  • EPS
  • SPRO N/A
  • FRGE N/A
  • Revenue
  • SPRO $44,584,000.00
  • FRGE $85,383,000.00
  • Revenue This Year
  • SPRO N/A
  • FRGE $18.22
  • Revenue Next Year
  • SPRO N/A
  • FRGE $29.35
  • P/E Ratio
  • SPRO N/A
  • FRGE N/A
  • Revenue Growth
  • SPRO N/A
  • FRGE 16.04
  • 52 Week Low
  • SPRO $0.51
  • FRGE $6.60
  • 52 Week High
  • SPRO $3.22
  • FRGE $23.85
  • Technical
  • Relative Strength Index (RSI)
  • SPRO 33.44
  • FRGE 43.13
  • Support Level
  • SPRO $2.30
  • FRGE $17.08
  • Resistance Level
  • SPRO $2.45
  • FRGE $17.80
  • Average True Range (ATR)
  • SPRO 0.12
  • FRGE 0.72
  • MACD
  • SPRO -0.07
  • FRGE -0.17
  • Stochastic Oscillator
  • SPRO 2.80
  • FRGE 18.00

About SPRO Spero Therapeutics Inc.

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

About FRGE Forge Global Holdings Inc.

Forge Global Holdings Inc is a financial service platform created to serve the needs of the private market. It provides marketplace infrastructure, data services, and technology solutions for private market participants. The company offers a trusted trading platform, proprietary data and insights to inform investment strategies, along with custody services to help companies, shareholders, institutions and accredited investors confidently navigate and transact in the private market.

Share on Social Networks: